Neal C Bradsher bought $6.0M of Lineage Cell Therapeutics (LCTX)

Executed Jan 27 2025, disclosed Jan 28 2025, 1 day later.

Value, as filed

$6.0M

7,894,737 sh × $0.76

Executed

Jan 27 2025

the trade date, as filed

Disclosed

Jan 28 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+0.0%

+0.0% from execution

Over the 21 trading sessions from the disclosed entry session (Jan 28 2025), the stock returned +0.0% (delay-adjusted); from the execution session (Jan 27 2025), +0.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

NB Neal C Bradsher Director profile →

Neal C Bradsher (Director) filed 3 Form 4 reports in the past 24 months (3 purchases, 0 sales), most often in STAA. Across 3 priced purchase filings, the average 21-session return was -2.4% from execution and -7.0% from disclosure (delay-adjusted; derived). The largest single filing was $6.3M of STAA (411,430 sh across 5 lots, as filed), executed Feb 12 2025.

The name

LCTX LCTX LCTX · 1 filing in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→